Dogwood Therapeutics
DWTX
25 hedge funds and large institutions have $308K invested in Dogwood Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0% more funds holding
Funds holding: 25 → 25 (0)
0% more ownership
Funds ownership: 0.28% → 0.28% (+0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
37% less capital invested
Capital invested by funds: $486K → $308K (-$178K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$28K |
| 2 |
Renaissance Technologies
New York
|
+$17.7K |
| 3 |
E
Ergoteles
New York
|
+$9.73K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.79K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$4.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$28K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$16K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$12.1K |
| 4 |
VF
Virtu Financial
New York
|
-$9.34K |
| 5 |
CA
Cetera Advisors
Denver,
Colorado
|
-$7.06K |
DWTX Hedge Fund Activity: Q4 2022 in Review
25 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q4 2022, worth a combined $308K — down 37% from $486K a quarter earlier.
Fund positioning in DWTX was balanced in Q4 2022: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 6 trimmed.
The largest buyer was Envestnet Asset Management, adding an estimated $28K. The largest seller was Vanguard Group, cutting an estimated $28K.
- 25 institutional investors held Dogwood Therapeutics (DWTX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $308K of Dogwood Therapeutics stock for Q4 2022, down 37% quarter-over-quarter.
- 3 funds opened new Dogwood Therapeutics positions in Q4 2022 and 3 closed out, a net change of 0 holders.
- The largest Dogwood Therapeutics buyer in Q4 2022 was Envestnet Asset Management, an estimated $28K added.
- The largest Dogwood Therapeutics seller in Q4 2022 was Vanguard Group, an estimated $28K sold.
Based on aggregated 13F filings for Q4 2022.